SynthesisPharmacoEconomics2009
Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.
Synthesis in PharmacoEconomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines.Clinical drug investigation · 2022Pooled it
- Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies.BMJ open · 2021Pooled it
- Pooled it
- Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Clinical drug investigation · 2015Pooled it
- Pooled it
- Trial
- Modelling epidemiological and economics processes - the case of cervical cancer.Health economics review · 2025Review
- Economic Burden of Cervical Cancer in Bulgaria.International journal of environmental research and public health · 2023Article
- Immunotherapy: Constructive Approach for Breast Cancer Treatment.Breast cancer (Dove Medical Press) · 2023Review
- Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands.Preventive medicine reports · 2022Article
- Revisiting time to translation: implementation of evidence-based practices (EBPs) in cancer control.Cancer causes & control : CCC · 2021Article
- HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.Papillomavirus research (Amsterdam, Netherlands) · 2019Article
- Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks.BMC medicine · 2018Article
- Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus.International journal of cancer · 2018Article
- Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China.BMC cancer · 2016Article
- The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.Cancer informatics · 2016Article
- Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.BMC infectious diseases · 2015Article
- Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.PharmacoEconomics · 2015Article
- Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?BMC infectious diseases · 2015Article
- The sexual ethics of HPV vaccination for boys.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2014Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent approval of human papillomavirus (HPV) vaccine means that decision makers need information beyond that available from randomized clinical trials to recommend funding for this vaccination programme. Modelling and economic studies have addressed some of those information needs. We conducted a qualitative systematic review to summarize the existing data. Review articles were obtained from an extensive literature search on studies using mathematical modelling (either a Markov or transmission dynamic model) to determine the effectiveness or cost effectiveness of an HPV vaccine compared with the current cytology-based Pap smear screening programme. A total of 21 studies (but 22 models) were included in the review after being assessed for methodological quality. All of the included studies had used a mathematical model to determine the effectiveness of an HPV vaccine, whilst 13 had also conducted a cost-effectiveness analysis. Although the studies used different model structures, baseline parameters and assumptions, all studies showed that vaccination would decrease rates of HPV infection, precancerous lesions and cervical cancer. Studies had a consistent message with respect to cost effectiveness: a female-only vaccination programme is cost effective compared with the current cytology-based Pap smear screening programme, while the cost effectiveness of a male and female vaccination programme is generally not cost effective compared with female-only vaccination.
Indexed as
Identifiers
19254046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.